RxDoctor Payments Data

Jose Rosales

Family · Las Cruces, NMNPI 1114118221

Payments from drug & device makers

$475in general payments, 2019–2025

Across 29 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$86
  • Amgen$69
  • AstraZeneca$44
  • Novartis$41
  • Novo Nordisk$38
  • Lilly USA, LLC$23
  • plus $175 from 11 others

What the payments were for

  • Food & beverage$475100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$475 in reported general payments places this provider in the 65th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$117,659
Medicare patients
221
Services billed
2,494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide118$149,365
TrulicityDulaglutide81$90,642
MounjaroTirzepatide63$88,342
EliquisApixaban42$51,137
FarxigaDapagliflozin Propanediol16$22,397
JanuviaSitagliptin Phosphate22$22,018
JanumetSitagliptin Phos/Metformin Hcl32$21,891
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)11$8,592
Levemir FlexpenInsulin Detemir19$6,241
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$5,910
Lactulose23$4,793
Gabapentin247$3,852
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro11$3,753
Omega-3 Acid Ethyl Esters39$3,710
SymbicortBudesonide/Formoterol Fumarate17$3,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$23$178,984144 claims
Novo NordiskOzempic$38$149,365118 claims
PfizerEliquis$17$51,13742 claims
AstraZenecaFarxiga, Symbicort$44$25,96833 claims
AbbVieSynthroid$13$2,46533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,080 family providers in New Mexico.

Other family in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →